AzTrials
AzTrials

HER2 Positive Gastric CancerPhase 1/2TACTIC-2NCT04727151

TAC T-cells for the Treatment of HER2-positive Solid Tumors

A Phase 1/2 study testing TAC01-HER2 and TAC01-HER2 plus pembrolizumab in people with HER2 Positive Gastric Cancer and Metastatic HER2 Positive Gastroesophageal Junction Cancer, run by Triumvira Immunologics, Inc. at 11 sites in 2 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
TAC01-HER2 and TAC01-HER2 plus pembrolizumab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
11 sitesin 2 countries
Study dates
19 Apr 2021to 25 Mar 2024
Phase
Phase 1/2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Written informed consent.
  • Age ≥ 18 years at the time of informed consent.
  • For Phase 1 and Phase 2:
  • Phase 1 monotherapy (completed): HER2 1+, 2+, 3+ by IHC by central laboratory confirmation
  • Phase 1 combination therapy and Phase 2: HER2 2+, 3+ by IHC and FISH by central laboratory confirmation
  • Histologically confirmed advanced, metastatic, unresectable solid tumors (regardless of PD-L1 expression levels; Phase 1 monotherapy) and histologically confirmed advanced, metastatic, unresectable gastric or esophageal adenocarcinoma (regardless of PD-L1 expression levels for Phase 1 combination therapy and Phase 2) after at least 2 prior lines of therapy (Phase 1) or after at least 2 and no more than 4 prior lines of therapy (Phase 2).
Show all 18Show fewer
  • HER2+ incurable malignancies for which no standard-of-care HER2 targeted therapy exists may be enrolled regardless of the number of prior treatment lines, as long as in the opinion of the investigator the subject would be unlikely to tolerate or derive clinically meaningful benefit from other available treatment options.
  • For breast cancer subjects, both prior lines of therapy must have included HER2-targeted agents per current standard-of-care.
  • Subjects with solid tumors with genetic alterations and mutations (such as BRAF, BRCA, EGFR mutations, and ALK translocation) where approved targeted therapies were available to their specific cancers must have been previously treated with such approved therapies or refused such approved targeted therapy for their cancers prior to enrollment, or in the opinion of the investigator would be unlikely to tolerate or derive clinically meaningful benefit from these standard-of-care therapies.
  • Measurable disease per RECIST 1.1 at time of enrollment.
  • ECOG performance status of 0 or 1 at Screening.
  • Life expectancy of at least 12 weeks.
  • Adequate organ and bone marrow reserve function.
  • Recovery to Grade ≤1 or Baseline for any toxicities due to previous therapy.
  • Adequate vascular access for leukapheresis.
  • Negative pregnancy test and use of highly effective contraception.
  • Undetectable HBV viral load.
  • HCV viral load is undetectable.

Who cannot join

  • Intolerant to any component of TAC01-HER2.
  • Prior treatment with any of the following:
  • Adoptive cell transfer of any kind, including CAR T cells
  • Gene therapy
  • Investigational medicinal product within 5 half-lives or 21 days prior to leukapheresis, whichever is shorter.
  • Receipt of a live or live-attenuated vaccine within 30 days prior to study treatment.
Show all 33Show fewer
  • Monoclonal antibody (mAb), including PD-1 and PD-L1, therapies within 21 days prior to leukapheresis.
  • Radiation within 28 days prior to enrollment. Palliative radiation is allowed up to 14 days prior to enrollment if non-irradiated lesions are present.
  • Chemotherapy or targeted small molecule therapy within 14 days prior to leukapheresis, or within 7 days prior to leukapheresis for erlotinib, gefitinib, afatinib, or crizotinib.
  • Colony stimulating factors, including granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin, and other hematopoietic cytokines, within 14 days prior to leukapheresis.
  • Immunosuppressive medication within 14 days or corticosteroid treatment < 72 hours prior to enrollment.
  • History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. (Brain metastasis - non-progressive or previously treated and currently stable - are permitted.)
  • Active inflammatory neurological disorders (e.g., Guillain-Barre Syndrome, amyotrophic lateral sclerosis, multiple sclerosis).
  • Active autoimmune disease (e.g., lupus, rheumatoid arthritis, Sjogren's syndrome) requiring systemic disease modifying agents in the past 2 years.
  • Active or uncontrolled hepatitis B or C (HCV ribonucleic acid [RNA] positive) infection or any history of or active human immunodeficiency virus (HIV) infection.
  • Uncontrolled, acute, or life-threatening bacterial, viral, or fungal infection. Subjects with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible if no evidence of active infection.
  • Class III or IV heart failure (as defined by the New York Heart Association - NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease within 6 months prior to Screening.
  • Cardiac arrhythmia not controlled by medical management.
  • Clinically significant thrombotic events within 6 months prior to leukapheresis and/or inability to stop anti-coagulation for at least 2 weeks prior to TAC01-HER2 infusion.
  • Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, non-metastatic squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  • Pregnant or lactating.
  • As determined by the Investigator, any uncontrolled medical, psychological, familial, sociological, or geographical condition(s) that do(es) not permit compliance with the protocol.
  • Participation in or has participated in a study using an investigational device within 4 weeks prior to study treatment..
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Combination Arm Only Specific Exclusions:
  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE).
  • Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  • Has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of trial treatment.
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Has history of an allogeneic stem cell transplant or a solid organ transplant.
  • Has a history of radiation pneumonitis. (Note: Cannot receive prior radiotherapy within 2 weeks of start of pembrolizumab. Note: Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week washout is permitted for palliative radiation [≤2 weeks of radiotherapy] to non-CNS disease).

Trial locations and contacts

11 sites in 2 countries.

11 sites in 2 countries

United States9 sites

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14203

  • Lurie Cancer Center - Northwestern University

    Chicago, Illinois, 60611

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio, 45267

  • MD Anderson Cancer Center

    Houston, Texas, 77030

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065

  • Rutgers Cancer Institute of New Jersey

    Newark, New Jersey, 08901

  • Sidney Kimmel Cancer Center - Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107

Other trials in United States

Canada2 sites

  • Centre Hospitalier de l'Université de Montréal/Montreal Hospital University Center (CHUM)

    Montreal, Quebec, H2X 0A9

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2C1

Other trials in Canada

About this study

Official title: A Phase 1/2 Trial Investigating the Safety and Efficacy of Autologous TAC T Cell Monotherapy, and TAC T Cells in Combination With Pembrolizumab, in Relapsed HER2-Positive Solid Tumors

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor.

This is an open-label, multicenter Phase 1/2 study that aims to establish safety, maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 as a monotherapy, and in combination with pembrolizumab, in subjects with HER2 positive gastric and gastroesophageal adenocarcinoma.

Read the detailed description

The TAC technology is a novel approach to modifying T cells, herein referred to as TAC T cells, and using them in the treatment of solid tumors. TAC T cells are produced through genetic engineering, incorporating TAC receptors into a patient's own T cells. This redirects these enhanced T cells to specific cancer antigens, and upon recognition, activates them through the natural signaling pathways of the endogenous TCR. In the TAC01-HER2 engineered T cell product; TAC T cells recognize the HER2 protein present on the surface of tumor cells, and eradicate them. Consequently, it is hypothesized TAC01-HER2 will be potentially safe and effective in treating patients with HER2+ solid tumors and provide a clinically meaningful therapeutic benefit in patient populations with high unmet medical need.

This is a first-in-human study investigating TAC01-HER2 to evaluate the safety, MTD or RP2D, PK, and efficacy in subjects with HER2+ solid tumors who have been treated after at least 2 lines of prior therapy in Phase 1 and after at least 2 lines and no more than 4 lines of prior therapy in Phase 2.

In Phase 1, escalating doses of TAC01-HER2 will be evaluated to identify the RP2D using the classic keyboard design method. The monotherapy arm will treat all subjects with HER2-positive solid tumors that meet the eligibility criteria (completed). The combination arm will treat all 2+ or 3+ HER2-positive subjects with gastric or gastroesophageal AC who meet the eligibility criteria.

In Phase 2, dose expansion groups will further evaluate the efficacy, safety, and PK of the MTD or RP2D for TAC01-CLDN18.2 in subjects with gastric and esophageal adenocarcinoma. In Phase 2, a Simon 3-stage design will be used to enroll up to 36 subjects in Group A (monotherapy arm) and 34 subjects in Group B (combination arm).

In summary:

  • Phase I monotherapy arm: Dose escalation in any HER2-positive solid tumor (completed).
  • Phase I combination therapy arm: Dose escalation in combination with pembrolizumab in 2+ or 3+ HER2-positive gastric and gastroesophageal adenocarcinoma
  • Phase II: Dose expansion cohorts: 2+ or 3+ HER2-positive gastric or gastroesophageal adenocarcinoma treated with TAC01-HER2 as a monotherapy (Group A) or in combination with pembrolizumab (Group B).
Being tested
TAC01-HER2, TAC01-HER2 plus pembrolizumab
Keywords
HER2 Positive Gastric Cancer, HER2 Positive gastroesophageal adenocarcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TAC01-HER2Biological

    TAC01-HER2 and:

    • fludarabine and cyclophosphamide, or
    • clofarabine and cyclophosphamide, or
    • bendamustine, or
    • cyclophosphamide

  • TAC01-HER2 plus pembrolizumabBiological

    Also called Keytruda

    TAC01-HER2 plus pembrolizumab and:

    • fludarabine and cyclophosphamide, or
    • clofarabine and cyclophosphamide, or
    • bendamustine, or
    • cyclophosphamide
Study groups in NCT04727151
Study groupRoleWhat they receive
TAC01-HER2ExperimentalLymphodepletion followed by TAC01-HER2 as a single IV infusion, with a potential for a second dose administration.
Receives: Biological: TAC01-HER2
TAC01-HER2 plus pembrolizumabExperimentalLymphodepletion followed by TAC01-HER2 as a single IV infusion, followed by pembrolizumab administration.
Receives: Biological: TAC01-HER2 plus pembrolizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phase 1: Incidence of Dose Limiting Toxicities (DLTs)

    A DLT is defined as:

    • Grade 4 or 5 events determined by the Investigator to be related to the investigational product, with the exception of Grade 4 laboratory abnormalities that are rapidly reversible or correctable without substantial safety concerns.
    • Grade ≥3 TAC T cell-associated acute infusion reactions persisting for ≥24 hours
    • Grade ≥3 TAC T cell-associated CRS or neurotoxicity persisting for ≥72 hours
    • Grade ≥3 cardiovascular or pulmonary toxicity persisting for ≥72 hours
    • Grade ≥3 immune-related toxicities
    • Grade ≥3 organ toxicities or non-hematologic toxicities that do not improve to baseline within 7 days
    • Clinically consequential Grade ≥3 neutropenia or thrombocytopenia lasting ≥30 days from TAC01-HER2 administration. Clinically consequential is defined as febrile neutropenia, serious infection, or bleeding events.

    Measured: 28 days

Secondary outcomes (8)

  1. Phase 1: Determine Recommended Phase 2 Dose (RP2D) for TAC01-HER2 Monotherapy

    RP2D was determined by the Data and Safety Monitoring Committee using the keyboard design method (<95% chance that the DLT rate exceeds 30%).

    Measured: Up to 28 Days Post TAC01-HER2 infusion

  2. Phase 1: Evaluate Overall Response Rate (ORR)

    Defined as the percentage of treated subjects with a complete or partial response (CR or PR) as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Measured: 24 months

  3. Phase 1: Evaluate Duration of Response (DoR)

    Defined as time from first response to disease progression, end of study, start of another anticancer therapy, or death

    Measured: 24 months

  4. Phase 1: Evaluate Overall Survival (OS)

    Defined as participants alive after 6 months

    Measured: 6 months

  5. Phase 1: Evaluate Disease Control Rate (DCR)

    Defined as the percentage of treated subjects with stable disease (SD), PR, and CR as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST)Version 1.1.

    Measured: 24 months

  6. Phase 1: Progression-Free Survival (PFS) or Time to Progression (TTP)

    Defined as time from infusion to disease progression or death from any cause

    Measured: 24 months

  7. Phase 1: Cmax of TAC01-HER2 (Pharmacokinetics; PK)

    Defined as the maximum concentration of TAC T cells after infusion; assessed by vector copy number

    Measured: Pre-treatment, days 3, 4 or 5, 8, 11, 14 or15, 18, 21 or 22, 25, 29, 42, months 3, 6, 9, 12, 18, 24 or end of study, and at the confirmatory progressive disease visit

  8. Phase 1 and Phase 2: Tmax of TAC01-HER2 (PK)

    Defined as the the first study day the Cmax is reached

    Measured: Pre-treatment, days 3, 4 or 5, 8, 11, 14 or15, 18, 21 or 22, 25, 29, 42, months 3, 6, 9, 12, 18, 24 or end of study, and at the confirmatory progressive disease visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2021
  2. Study start19 Apr 2021
  3. Primary completion17 Dec 2023
  4. Study completion25 Mar 2024

Why it stopped: Study terminated by Sponsor for commercial reasons

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Model description
In Phase 1, escalating doses of TAC01-HER2 will be evaluated to identify the RP2D of the monotherapy arm and the combination arm using the classic keyboard design. In Phase 2, dose expansion groups will further evaluate the safety, efficacy, and PK of the MTD or RP2D for TAC01-HER2 as a monotherapy and in combination with pembrolizumab in subjects with gastric and gastroesophageal adenocarcinoma.
Masking
None (open label)
Enrolment
28 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04727151
Sponsor's protocol ID
TAC01-HER2-03
Other IDs
KEYNOTE-E77
Acronym
TACTIC-2
Status last verified
Jun 2025
First submitted
20 Jan 2021
Last updated
8 Jun 2025
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing TAC01-HER2 and TAC01-HER2 plus pembrolizumab in people with HER2 Positive Gastric Cancer and Metastatic HER2 Positive Gastroesophageal Junction Cancer, run by Triumvira Immunologics, Inc. at 11 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 8 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 11 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Jun 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phase 1: Incidence of Dose Limiting Toxicities (DLTs) (time frame: 28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04727151.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in